Kymera Therapeutics, Inc.

This study is testing a new oral medication, KT-621, for people with moderate to severe atopic dermatitis (eczema). For 16 weeks, some participants will receive the drug while others get a placebo, followed by a year where everyone can receive the active treatment. The main goals…

This study is testing a new oral medication called KT-621 for adults with a specific type of moderate-to-severe asthma that remains uncontrolled despite using standard high-dose inhaler medications. Researchers aim to see if the pill improves lung function and asthma control whil…

This is the first study to give a new oral drug called KT-579 to people. Its main goal is to check if the drug is safe and how the body processes it in healthy adult volunteers. Researchers will test different single and repeated doses, comparing them to a placebo, to gather init…